文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

追踪细胞疗法以优化对肝转移灶的归巢作用。

Tracking cellular therapies to optimize homing against liver metastases.

作者信息

Purl Megan C, Shick Alexandria, Canter Robert J, Judge Sean J

机构信息

University of California Davis Health, Division of Surgical Oncology, Department of Surgery, Sacramento, CA, United States.

Comprehensive Cancer Center, University of California, Davis, Sacramento, CA, United States.

出版信息

Front Immunol. 2025 Jun 25;16:1611861. doi: 10.3389/fimmu.2025.1611861. eCollection 2025.


DOI:10.3389/fimmu.2025.1611861
PMID:40636106
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12238001/
Abstract

Novel cellular therapies have shown practice changing results in a range of hematologic malignancies, though success against solid tumors has been limited. Key factors limiting success of these therapies against solid tumors are homing to the site(s) of disease, engraftment, maintenance of function, and persistence. The inhospitable tumor microenvironment appears to provide barriers at every step of this process. The liver, a unique organ with diverse immunoregulatory functions, is a common site for metastatic disease from solid cancers of the gastrointestinal (GI) tract. Although the complex interplay between hepatocytes, circulatory and tissue resident immune cells, and the enterohepatic circulation has been investigated for some time, many unanswered questions about the immunobiology of the liver remain. More so, novel imaging techniques provide unparalleled insight into these interactions and shed light on these complex processes that can lead to an improved understanding of the tumor microenvironment in the liver and opportunities for improving homing of cellular therapy against liver tumors. In this review, we will provide a focused assessment of this burgeoning field and focus on the emerging tools for studying homing of these therapies and how they may be enhanced to better treat liver metastases.

摘要

新型细胞疗法已在一系列血液系统恶性肿瘤中显示出改变临床实践的效果,不过在实体瘤治疗方面的成功有限。限制这些疗法在实体瘤治疗中取得成功的关键因素包括归巢至疾病部位、植入、功能维持和持久性。恶劣的肿瘤微环境似乎在这一过程的每一步都构成了障碍。肝脏是一个具有多种免疫调节功能的独特器官,是胃肠道实体癌转移疾病的常见部位。尽管肝细胞、循环和组织驻留免疫细胞以及肠肝循环之间的复杂相互作用已被研究了一段时间,但关于肝脏免疫生物学仍有许多未解决的问题。更重要的是,新型成像技术为这些相互作用提供了无与伦比的见解,并揭示了这些复杂过程,有助于更好地理解肝脏中的肿瘤微环境,以及改善细胞疗法对肝肿瘤归巢的机会。在本综述中,我们将对这一新兴领域进行重点评估,并关注研究这些疗法归巢的新兴工具,以及如何增强这些工具以更好地治疗肝转移瘤。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e3c/12238001/7a47b8775868/fimmu-16-1611861-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e3c/12238001/7a47b8775868/fimmu-16-1611861-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e3c/12238001/7a47b8775868/fimmu-16-1611861-g001.jpg

相似文献

[1]
Tracking cellular therapies to optimize homing against liver metastases.

Front Immunol. 2025-6-25

[2]
The Black Book of Psychotropic Dosing and Monitoring.

Psychopharmacol Bull. 2024-7-8

[3]
Short-Term Memory Impairment

2025-1

[4]
The Lived Experience of Autistic Adults in Employment: A Systematic Search and Synthesis.

Autism Adulthood. 2024-12-2

[5]
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.

Health Technol Assess. 2001

[6]
Management of urinary stones by experts in stone disease (ESD 2025).

Arch Ital Urol Androl. 2025-6-30

[7]
NIH Consensus Statement on Management of Hepatitis C: 2002.

NIH Consens State Sci Statements. 2002

[8]
Assessing the comparative effects of interventions in COPD: a tutorial on network meta-analysis for clinicians.

Respir Res. 2024-12-21

[9]
Autistic Students' Experiences of Employment and Employability Support while Studying at a UK University.

Autism Adulthood. 2025-4-3

[10]
Sexual Harassment and Prevention Training

2025-1

本文引用的文献

[1]
Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial.

J Clin Oncol. 2024-11-10

[2]
Proton radiation boosts the efficacy of mesothelin-targeting chimeric antigen receptor T cell therapy in pancreatic cancer.

Proc Natl Acad Sci U S A. 2024-7-30

[3]
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results.

Nat Med. 2024-8

[4]
Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development.

Mol Ther. 2023-11-1

[5]
Tumor-Targeted Nonablative Radiation Promotes Solid Tumor CAR T-cell Therapy Efficacy.

Cancer Immunol Res. 2023-10-4

[6]
Current and potential roles of immuno-PET/-SPECT in CAR T-cell therapy.

Front Med (Lausanne). 2023-6-27

[7]
Combination of CAR‑T cell therapy and radiotherapy: Opportunities and challenges in solid tumors (Review).

Oncol Lett. 2023-5-16

[8]
CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks.

Mol Cancer. 2023-5-12

[9]
Long-term outcomes following CAR T cell therapy: what we know so far.

Nat Rev Clin Oncol. 2023-6

[10]
Cancer statistics, 2023.

CA Cancer J Clin. 2023-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索